Non-invasive treatment of sarcoma

Share This Post

Precise radiotherapy is the most important method of cancer treatment. Precise radiotherapy techniques represented by rapid front knife, proton knife, heavy ion, etc., can perform radical surgery and auxiliary treatment for cancer patients. To understand the progress of radiotherapy, sarcoma is more common in young people, is a malignant tumor derived from mesenchymal tissue (including connective tissue and muscle). Sarcomas are highly malignant and develop rapidly! Common sarcomas include osteosarcoma, leiomyoma, lymphosarcoma, synovial sarcoma, etc.   
The preferred method of sarcoma is surgery. In order to seek a radical cure, domestic doctors usually require patients to have their limbs amputated. , Most patients are difficult to treat. Sarcoma is not sensitive to chemotherapy. Ordinary radiotherapy is also difficult to kill tumors, and leiomyoma, lymphosarcoma, and synovial sarcoma are prone to metastasis through the blood. Therefore, the treatment of sarcoma must be as soon as possible and as soon as possible.

The EDGE Radiosurgery system (EDGE radiosurgery tumor treatment system) was developed by the American Varian company and was approved by the US FDA on January 23, 2013. The EDGE blade is by far the most effective non-invasive tumor removal technology, using the unique FDA’s Calypso® GPS for the Body® system and surface beam monitoring system approved on July 21, 2014 with high-frequency real-time dynamics of up to 10 ms Monitor and lock the tumor “escape” during the treatment process, combined with the new generation IGRT and other image guidance technology, using the unique high-intensity HD-MLC collimator up to 2400MU / min to remove tumor tissue with sub-millimeter accuracy with almost no residue . 

The unique characteristics of EDGE speed knife, high-intensity radiation of up to 2400MU / min, can quickly break the DNA of tumor cells, and eventually cause the tumor cells to die, and the tumor is absorbed or scarred. The accuracy of the EDGE knife is as high as 0.1mm. 

 

For details on sarcoma treatment and second opinion, do call us at +91 96 1588 1588 or write to cancerfax@gmail.com.

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Polatuzumab
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form

https://cancerfax.com/